Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.

This report describes a case of severe hair loss with accompanying thyroid issues and eczema that improved noticeably after individualized homeopathic treatment, following unsuccessful previous methods, as observed at Dr Batra’s® Homeopathy Clinic.

In this study, researchers introduced the Sanusi FUE Score Scale to better predict and grade the difficulty of follicular unit excision hair transplantation by accounting for diverse hair and skin types, with further validation needed.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

In this study, serum from patients with alopecia areata or universalis did not affect hair growth in transplanted scalp skin grafts on nude mice, despite increased deposition of immunoreactants.

This study suggests that autoimmune dysregulation involving HLA-DR+ T and NK cell subsets may contribute to severe patchy alopecia areata and alopecia universalis, with normalization seen after betamethasone treatment.

This letter discusses alopecia universalis and Kallman’s Syndrome, and offers no new clinical results.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

This study identified several significant genetic variants associated with alopecia universalis, including a novel association with HLA-DRB5, which may play a hidden role in the disease.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This retrospective cohort study found that individuals with alopecia totalis or universalis have a higher prevalence of systemic autoimmune diseases, particularly endocrine diseases and inflammatory bowel disease, compared to those with patchy alopecia areata.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

This report documents a rare case of alopecia universalis in an HIV-positive patient in Portugal, highlighting the changing comorbidity spectrum in this population due to increased life expectancy from antiretroviral therapy.

This study identifies a mutation in the hairless gene that may impact thyroid receptor interaction, contributing to alopecia universalis congenita in an Arab Israeli patient.

This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.

This report describes a case of alopecia areata returning as AA universalis in a 63-year-old woman after receiving the SARS-CoV-2 vaccine, following a 32-year remission.

This review discusses the roles of the hairless (HR) protein as a corepressor, particularly its impact on RORα-mediated transcriptional repression, and reports no new experimental findings.

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study found that biologic therapies, particularly anti-TNF-alpha agents, have been linked to increased cases of alopecia areata in patients treated for autoimmune disorders.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.